The Laboratory's Role in Opioid Pain Medication Monitoring.
Opioid analgesics are the most potent pain medications therefore they are often used for the treatment of chronic malignant and non-malignant pain. Their strong addictive potential requires close monitoring of patients on opioid therapy for possible non-compliance with prescriptions, for drug diversion, and for proof of avoidance of non-prescribed or illicit opioids. Monitoring can be performed by urine drug screens or qualitative or quantitative drug confirmation assays. Natural, semi-synthetic and synthetic opioids have dissimilar chemical structures and they undergo extensive metabolism. Phase one metabolic reactions of opioids can produce other opioids with similar structures to other, non-prescribed medications. Only detailed and concurrent analysis of parent drugs and metabolites can provide accurate clinical information regarding patient compliance. Traditional immunoassays, often used for urine drug screening, react with only a small number of opioids or only with a single medication and they exhibit variable cross reactivity with their phase two metabolites. Additionally the limit of detection of these immunoassays may not be sufficient for medical purposes, therefore clinical interpretation of immunoassay test results can be challenging. Recently liquid chromatography, mass spectrometry (LCMSMS) based assays have been adapted by many clinical laboratories. These LCMSMS tests can provide information about the presence of several opioids and their metabolites in a single sample at clinically meaningful detection limits, allowing accurate assessment of patient compliance. This review article will investigate in details the various opioids, their metabolism and the challenges the testing laboratories and ordering clinicians face.
Veterans Administration, Eastern Colorado Health Care System (VA ECHCS) , Denver.
Geza S
GS
Bodor
LCMSMS; Opiates; codeine; immunoassay; morphine; opioids; pain medication monitoring; semi-synthetic opiates; urine drug screen
Arch Pediatr Adolesc Med. 2006 Feb;160(2):146-50
16461869
J Forensic Sci. 1997 Jul;42(4):741-3
9243844
Drug Alcohol Depend. 2012 Sep 1;125(1-2):160-3
22483811
J Pharm Biomed Anal. 1999 Sep;20(5):815-28
10701990
J Palliat Med. 2007 Apr;10(2):465-75
17472518
Am J Forensic Med Pathol. 2004 Jun;25(2):178-81
15166776
J Anal Toxicol. 1990 Nov-Dec;14(6):385-7
2087101
Ann Clin Biochem. 2009 Jan;46(Pt 1):50-7
19103958
Am J Forensic Med Pathol. 2011 Jun;32(2):131-5
21030851
J Anal Toxicol. 2012 Jan-Feb;36(1):12-8
22290747
J Anal Toxicol. 1995 Jan-Feb;19(1):18-26
7536861
J Forensic Sci. 1996 Mar;41(2):320-1
8871394
J Anal Toxicol. 2010 Jan-Feb;34(1):17-25
20109298
Pain Physician. 2010 Jan-Feb;13(1):E1-E22
20119473
Ann Clin Lab Sci. 2007 Autumn;37(4):301-14
18000286
Vital Health Stat 13. 2006 Feb;(159):1-66
16471269
Pain Med. 2012 Jul;13(7):886-96
22694154
Clin Chem. 1997 Jun;43(6 Pt 1):1029-32
9191557
CMAJ. 1998 Feb 10;158 Suppl 3:S71-81
9484281
BMC Health Serv Res. 2006 Apr 04;6:46
16595013
J Palliat Med. 2007 Dec;10(6):1253-5
18095801
Forensic Sci Int. 2012 Feb 10;215(1-3):18-24
21353406
J Anal Toxicol. 2012 May;36(4):239-49
22511698
Curr Drug Abuse Rev. 2011 Dec;4(4):292-7
21834754
J Opioid Manag. 2007 Mar-Apr;3(2):80-6
17520987
J Anal Toxicol. 1991 Jul-Aug;15(4):161-6
1943064
Br J Pharmacol. 2000 Dec;131(7):1422-8
11090116